alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.2

LOGO



AMENDED STOCK PURCHASE AGREEMENT

This amended
agreement made and entered into by and between Ralph T. Hurley and wife, Willa Dean Hurley hereinafter referred to as (Seller) and Volunteer Bancorp, Inc., a corporation organized and existing under the laws of the State of Tennessee,
hereinafter referred to as (Volunteer).

WHEREAS, Seller and Volunteer entered into a Stock
Purchase Agreement dated April 13, 2006 providing for the purchase by Volunteer of all Sellers shares of the common stock (stock) of Volunteer in four (4) equal annual transactions to be concluded on or before
June 1, 2009, the (Purchase Price); and

WHEREAS, one-half of the stock of Seller has now been
conveyed to Volunteer pursuant to the aforesaid Stock Purchase Agreement, and the third equal transaction is scheduled to take place on or before June 1, 2008 with the last equal transaction scheduled to take place on or before June 1,
2009; and

WHEREAS, Volunteer desires to extend the final two transaction dates to provide that the third equal
transaction shall take place subsequent to January 1, 2010 and prior to June 1, 2010, and the fourth equal transaction shall take place subsequent to January 1, 2011 and prior to June 1,2011; and,

WHEREAS, Seller is agreeable to the modification as hereinabove set forth;

NOW, THEREFORE, WITNESSETH that for and in consideration of the sum of Ten ($10.00) Dollars in hand paid by Volunteer to
Seller, and other good and valuable consideration as hereinabove and hereinafter set forth the parties do hereby agree as follows:

1. The Stock Purchase Agreement, a copy of which is attached hereto, be and hereby is amended by deleting therefrom Paragraph 2 c.) and Paragraph 2 d.) and by substituting therefore the
following:

2.

c.) Subsequent to January 1, 2010 and prior to June 1, 2010

Volunteer shall pay to Seller the sum of $470,250.00 and Seller shall deliver to Volunteer 21,375 shares. (one-fourth of the total shares of stock)

d.) Subsequent to January 1, 2011 and prior to June 1, 2011

Volunteer shall pay to Seller the sum of $470,250.00 and Seller shall deliver to Volunteer 21,375 shares. (the remaining
shares of Sellers stock)

2. Volunteer shall pay to Seller five (5%) percent interest per annum on
the outstanding balance of any installment due or unpaid under the timetable for payments as established in the original Stock Purchase Agreement. Said interest payments shall be



---

LOGO



made
monthly to Seller, and shall be paid on or before the 15th day of each month in which any outstanding balance of any installment due or unpaid exists.

3. Nothing herein shall prevent Volunteer from voluntarily prepaying any installment prior to the due date set forth herein.

4. All other provisions of the Stock Purchase Agreement shall remain in full force and effect without amendment thereto.

IN WITNESS WHEREOF the parties have hereunto set their hands on this the 16th day of July, 2008.

Witness V

Ralph T. Hurley



Witness

Willa Dean Hurley

VOLUNTEER BANCORP, Inc.

By: Reed Matney



Title: President
IN THE DISTRICT COURT OF APPEAL OF THE STATE O F FLORIDA

FIFTH DISTRICT

NOT FINAL UNTIL TIME E XPIRES TO

FILE MOTION FOR REHEARING AND

DISPOSITION THEREOF IF FILED

LEROY WILLIAMS, III

,

Appellant

,

v. Case No. 5D 22

- 2284

LT Case No. 2009

- CF

- 1232

- A

STATE OF FLORIDA

,

Appellee

.

________________________________/

Decision filed February 7, 2023

3.850 Appeal from the Circuit Court

for Seminole County

, Donna L. Mcintosh , Judge.

Leroy Williams, I II

, Perry, pro se.

No Appearance for Appellee.

PER CURIAM.

AFFIRMED.

LAMBERT, C.J.

, EVANDER and HARRIS , JJ., concur.
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 97-40053

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

CHUCKY RAY JOHNSON, SR.,

Defendant-Appellant.

- - - - - - - - - -

Appeal from the United States District Court

for the Eastern District of Texas

USDC No. 1:93-CR-214

- - - - - - - - - -

December 9, 1997

Before BARKSDALE, BENAVIDES, and STEWART, Circuit Judges. 

PER CURIAM:*

Chucky Ray Johnson, Sr., appeals his convictions and

sentence for conspiracy to possess with intent to distribute

cocaine base and possession with intent to distribute cocaine

base. Johnson argues that the evidence is insufficient to

support his convictions and that the district court clearly erred

in determining the quantity of cocaine base on which his sentence

should be based. Having reviewed the record and the briefs of

the parties, we AFFIRM.
§ 530.11 Limitations. In addition to uses which do not comply with the provision set forth in § 530.10, the following specific extralabel uses are not permitted and result in the drug being deemed unsafe within the meaning of section 512 of the act: ( a ) Extralabel use in an animal of an approved new animal drug or human drug by a lay person (except when under the supervision of a licensed veterinarian);
( b ) Extralabel use of an approved new animal drug or human drug in or on an animal feed;
( c ) Extralabel use resulting in any residue which may present a risk to the public health; and
( d ) Extralabel use resulting in any residue above an established safe level, safe concentration or tolerance.
I 

118TH CONGRESS 

2D SESSION H. R. 7356 

To require Members of Congress who advocate for providing military support 

for Ukraine to enlist in the Armed Forces and to serve on active duty 

in support of a contingency operation. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 14, 2024 

Mrs. LUNA (for herself and Ms. GREENE of Georgia) introduced the following 

bill; which was referred to the Committee on House Administration, and 

in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such 

provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To require Members of Congress who advocate for providing 

military support for Ukraine to enlist in the Armed 

Forces and to serve on active duty in support of a 

contingency operation. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Senators Can Help 

5 Underpin Military Engagement and Readiness Act’’ or the 

6 ‘‘SCHUMER Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7356 IH

1 SEC. 2. REQUIRING MEMBERS OF CONGRESS ADVOCATING 

2 FOR MILITARY SUPPORT FOR UKRAINE TO 

3 ENLIST IN ARMED FORCES AND SERVE ON 

4 ACTIVE DUTY IN SUPPORT OF CONTINGENCY 

5 OPERATIONS. 

6 (a) REQUIREMENT.—If a Member of Congress advo7 cates for providing military support for Ukraine, the Mem8 ber— 

9 (1) shall enlist in the Army, Navy, Air Force, 

10 Marine Corps, Space Force, or Coast Guard; and 

11 (2) shall be assigned for not fewer than 6 

12 months to active duty in support of a contingency 

13 operation. 

14 (b) MEMBER OF CONGRESS DEFINED.—In this Act, 

15 the term ‘‘Member of Congress’’ means a Senator or a 

16 Representative in, or Delegate or Resident Commissioner 

17 to, the Congress. 

18 (c) CONTINGENCY OPERATION DEFINED.—In this 

19 Act, the term ‘‘contingency operation’’ means a military 

20 operation that— 

21 (1) is designated by the Secretary of Defense as 

22 an operation in which members of the Armed Forces 

23 are or may become involved in military actions, oper24 ations, or hostilities against an enemy of the United 

25 States or against an opposing military force; or 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7356 IH

1 (2) results in the call or order to, or retention 

2 on, active duty of members of the uniformed services 

3 under section 688, 12301(a), 12302, 12304, 

4 12304a, 12305, or 12406 of title 10, United States 

5 Code, chapter 13 of such title, section 3713 of title 

6 14, United States Code, or any other provision of 

7 law during a war or during a national emergency de8 clared by the President or Congress. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   3-MOS
<FISCAL-YEAR-END>                          JAN-02-1999             JAN-03-1998
<PERIOD-START>                             JAN-04-1998             DEC-29-1996
<PERIOD-END>                               APR-04-1998             MAR-29-1997
<CASH>                                         110,000                 114,000
<SECURITIES>                                         0                       0
<RECEIVABLES>                               36,400,000              37,447,000
<ALLOWANCES>                                 2,263,000               2,686,000
<INVENTORY>                                 58,698,000              54,305,000
<CURRENT-ASSETS>                           108,390,000             104,224,000
<PP&E>                                      78,078,000              68,810,000
<DEPRECIATION>                               7,334,000               5,981,000
<TOTAL-ASSETS>                             181,760,000             169,351,000
<CURRENT-LIABILITIES>                       43,997,000              36,356,000
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                             0                       0
<OTHER-SE>                                  88,882,000              88,882,000
<TOTAL-LIABILITY-AND-EQUITY>               181,760,000             169,351,000
<SALES>                                     56,825,000              58,932,000
<TOTAL-REVENUES>                            56,825,000              58,932,000
<CGS>                                       48,958,000              54,258,000
<TOTAL-COSTS>                               48,958,000              54,258,000
<OTHER-EXPENSES>                             5,682,000               5,453,000
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                          (2,074,000)             (1,248,000)
<INCOME-PRETAX>                                111,000              (2,191,000)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                            111,000              (2,191,000)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   111,000              (2,191,000)
<EPS-PRIMARY>                                     0.01                   (0.22)
<EPS-DILUTED>                                     0.01                   (0.22)
        

</TABLE>
**Exhibit 31.2**

**CERTIFICATION**

I, Richard J. Baum, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 
| Date:  | August 14, 2006 | /s/ Richard J. Baum     |   |
|--------|-----------------|-------------------------|--------|
|   |            | Richard J. Baum         |   |
|   |            | Chief Financial Officer |   |

 

 

----
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5470 Hemoglobin immunological test system. ( a ) *Indentification.* A hemoglobin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the different types of free hemoglobin (the oxygen-carrying pigment in red blood cells) in blood, urine, plasma, or other body fluids. Measurements of free hemoglobin aid in the diagnosis of various hematologic disorders, such as sickle cell anemia, Fanconi's anemia (a rare inherited disease), aplastic anemia (bone marrow does not produce enough blood cells), and leukemia (cancer of the blood-forming organs).
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 84 FR 71800, Dec. 30, 2019]
§ 640.76 Products stored or shipped at unacceptable temperatures. ( a ) *Storage temperature.* ( 1 ) Except as provided in paragraph (a)(2) of this section, Source Plasma intended for manufacture into injectable products that is inadvertently exposed (i.e., an unforeseen occurrence in spite of compliance with good manufacturing practice) to a storage temperature warmer than −20 °C and colder than + 10 °C may be issued only if labeled as “Source Plasma Salvaged.” The label shall be revised before issuance, and appropriate records shall be maintained identifying the units involved, describing their disposition, and explaining fully the conditions that caused the inadvertent temperature exposure.
( 2 ) Source Plasma intended for manufacture into injectable products that is exposed inadvertently (i.e., an unforeseen occurrence in spite of compliance with good manufacturing practice) to one episode of storage temperature fluctuation that is warmer than −20 °C and colder than −5 °C for not more than 72 hours is exempt from the labeling requirements of paragraph (a)(1) of this section, provided that the plasma has been and remains frozen solid. Appropriate records shall be maintained identifying the units involved, describing their disposition, explaining fully the conditions that caused the inadvertent temperature exposure, and documenting that the episode of temperature elevation did not exceed 72 hours, that the temperature did not rise to warmer than −5 °C in storage, and that the plasma remained frozen solid throughout the period of elevated temperature. When requested, copies of the records shall be provided to the plasma derivative manufacturer.
( b ) *Shipping temperature.* If Source Plasma for manufacture into injectable products is exposed inadvertently (i.e., an unforeseen occurrence in spite of compliance with good manufacturing practice) to a shipping temperature warmer than −5 °C and colder than + 10 °C, the plasma derivative manufacturer shall label it “Source Plasma Salvaged.” Appropriate records shall be maintained identifying the units involved, describing their disposition, and explaining fully the conditions that caused the inadvertent temperature exposure.
( c ) *Relabeling.* If Source Plasma is required to be relabeled as “Source Plasma Salvaged” under paragraph (a)(1) or (b) of this section, the person responsible for the relabeling shall cover the original label with either ( 1 ) a complete new label containing the appropriate information or
( 2 ) a partial label affixed to the original label and containing the appropriate new information, which covers the incorrect information regarding storage temperature.
[45 FR 80501, Dec. 5, 1980, as amended at 50 FR 4140, Jan. 29, 1985]
#### § 558.582 Sulfamerazine.

(a) *Specifications.* Type A medicated articles containing 99 percent sulfamerazine.

(b) *Sponsor.* See No. 054771 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Related tolerances.* See [§ 556.660 of this chapter](/on/2024-09-17/title-21/section-556.660).

(d) *Special considerations.*

(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See [§ 558.6](/on/2024-09-17/title-21/section-558.6) for additional requirements.

(2) The expiration date of VFDs for sulfamerazine medicated feeds must not exceed 6 months from the date of issuance. VFDs for sulfamerazine shall not be refilled.

(e) *Conditions of use.* It is used in fish feed for as follows:

| Sulfamerazine grams/ton | Combination in grams/ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (1) To deliver 10 grams of sulfamerazine per 100 pounds of fish per day | | Rainbow trout, brook trout, and brown trout: For control of furunculosis | Formulate to deliver 10 grams of sulfamerazine per 100 pounds of fish per day. Treat for not more than 14 days. Do not treat within 3 weeks of marketing or stocking in stream open to fishing | 054771 |
| (2) [Reserved] | | | | |

[[81 FR 95013](https://www.federalregister.gov/citation/81-FR-95013), Dec. 27, 2016]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3100 Amphetamine test system. ( a ) *Identification.* An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.
( b ) *Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
[52 FR 16122, May 1, 1987, as amended at 84 FR 71797, Dec. 30, 2019]
##### 



EXHIBIT 99.3
 EverQ GmbH, Thalheim
 Cash Flow Statement
for the period from December 20, 2006 to December 31, 2006
 December 20 toDecember 31,2006Net Income
    
    
    1,190,337.21Depreciation and amortization
    
    
    231,764.35Reversal of grants
    
    
    -164,433.68Decrease in accrued expenses
    
    
    -2,704,763.70Increase in inventories, receivables and other assets
    
    
    -3,671,515.34Increase in other current liabilities
    
    
    1,153,753.24Net cash used by operating activities
    
    
    -3,964,857.92Acquisition of fixed assets
    
    
    -2,951,396.84Net cash used by investing activities
    
    
    -2,951,396.84Repayments of long-term liabilities to banks
    
    
    -500,000.00Repayments of short-term liabilities to banks
    
    
    -6,800,000.00Net cash used by financing activities
    
    
    -7,300,000.00Net reduction in cash
    
    
    -14,216,254.76Cash at the beginning of period
    
    
    58,719,483.24Cash at the end of period
    
    
    44,503,228.48